logo-loader
viewCB2 Insights Inc.

CB2 Insights CEO says company is on track to profitability in 2Q

The company’s focus on execution allowed it to achieve solid revenue growth since going public last March

pot stocks arrow
CB2 generated C$10.3 million in yearly revenue up to 3Q 2019

CB2 Insights Inc (CSE:CBII) (OTCMKTS:CBIIF) CEO Prad Sekar told shareholders Wednesday that the cannabis analytics company is on track to be profitable by its fiscal second-quarter 2020. 

The company’s focus on execution allowed it to achieve solid revenue growth since going public in March 2019, according to Sekar. 

The CEO wrote in a letter to shareholders that CB2 is on track to build and develop the industry’s largest data bank of anonymized clinical data on the safety, efficacy and usage of medical cannabis-based products and delivery forms. 

READ: CB2 Insights to study effects of hemp CBD on patients with anxiety in partnership with GL Brands

Toronto-based CB2 now owns and operates one of the largest multi-state networks of specialty clinics in the US, assessing nearly 100,000 patients seeking treatment. The clinic network provides immediate market access to US-based product manufacturers for clinical trial and research programs, according to Sekar.

The company also built electronic data capture and clinical data management software tools for clients such as Drug Science (Project T21), VIVO Cannabis, FCM Global, Premier Health, and My Access Clinics.

According to its most recent financials, CB2 generated year to date revenue of C$10.3 million up to 3Q 2019.

Sekar said that that CB2’s latest warrant repricing program has good support and uptake by shareholders and offered the firm the “most equitable” form of non-dilutive capital.

“We have truly transformed our operation not only to reach profitability,” Sekar wrote, “but to pursue opportunities that will elevate the position of CB2 Insights as a valuable provider of data and research to stakeholders in both the medical cannabis and life science verticals.”

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: CB2 Insights Inc.

Price: 0.125 CAD

CSE:CBII
Market: CSE
Market Cap: $10 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CB2 Insights Inc. named herein, including the promotion by the Company of CB2 Insights Inc. in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CB2 Insights announces key partnership with GL Brands for...

CB2 Insights ((CSE: CBII; OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from our Toronto studio to provide details the will begin a prospective trial with GL Brands that will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules...

on 17/12/19

2 min read